UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.67 USD | -0.85% |
|
-2.30% | -31.02% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
| Sales 2024 * | 55.57M 59.2M | Sales 2025 * | 78.26M 83.36M | Capitalization | 212M 226M |
|---|---|---|---|---|---|
| Net income 2024 * | -202M -215M | Net income 2025 * | -182M -194M | EV / Sales 2024 * | 2.82 x |
| Net cash position 2024 * | 55.78M 59.42M | Net cash position 2025 * | 50.83M 54.15M | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-1.24
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | -0.85% | ||
| 1 week | -2.30% | ||
| Current month | -10.19% | ||
| 1 month | -8.97% | ||
| 3 months | -15.86% | ||
| 6 months | -24.43% | ||
| Current year | -31.02% |
1 week
4.61
4.83
1 month
4.615.48
Current year
4.617.12
1 year
4.6122.48
3 years
4.6138.80
5 years
4.6182.49
10 years
4.6182.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 16 M€ | -9.75% | ||
| 0.48% | 29 M€ | -5.60% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 4.67 | -0.85% | 547,860 |
| 24-04-18 | 4.71 | +0.86% | 440,845 |
| 24-04-17 | 4.67 | -0.64% | 825,647 |
| 24-04-16 | 4.7 | -0.84% | 432,949 |
| 24-04-15 | 4.74 | -0.84% | 669,356 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-04-28
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.378
EUR
Average target price
18.98
EUR
Spread / Average Target
+333.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.02% | 226M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +19.90% | 10.85B | |
| -23.23% | 8.4B |
- Stock Market
- Equities
- QURE Stock
